First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

Exclusion Criteria

• •Signed written informed consent.
• •Aged less than 16 years old.
• •Eastern Cooperative Oncology Group (ECOG) performance status \>2.
• •Participants with inadequate biological tests.
• •White blood cell count \> 30,000 per cubic millimeter.
• •History of active or chronic autoimmune conditions that had required or requires therapy.
• •Graft-versus-host disease following allogeneic stem cell transplantation required treatment with more than 10 milligrams (mg) of oral prednisone or equivalent daily. The stem cell transplant and/or donor lymphocyte infusion should had been performed more than 3 months before study treatment start.
• •Second primary malignancy that required active therapy. Adjuvant hormonal therapy was allowed.
• •Previous treatment with radiotherapy or immunotherapeutic agents in the 4 weeks prior to investigational medicinal product (IMP) administration.
• •Previous treatment with any other investigational agent in the 4 weeks prior to IMP administration.
• •Receiving, at the time of first IMP administration, of concurrent steroids \>10 mg per day of oral prednisone or the equivalent for \>=3 months.
• •Requirement for tocilizumab for any other diagnosis.
• •Evidence of active central nervous system leukemia at the time of enrollment.
• •Acquired immunodeficiency syndrome (AIDS-related illnesses) or human immunodeficiency virus disease requiring antiretroviral treatment or had active Hepatitis B viral infection or Hepatitis C viral infection.
• •Women of childbearing potential, male with a partner of childbearing potential who did not agree to use effective methods of birth control.
• •Any clinically significant, uncontrolled medical conditions that, in the Investigator's opinion, would expose excessive risk to the participant or may interfere with compliance or interpretation of the study results.
• •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.